A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 in Non-proliferative Diabetic Retinopathy (NPDR)

NCT05066230 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

253

Enrollment

INDUSTRY

Sponsor class

Stopped All patients completed the primary endpoint assessments. Additional follow-up after the primary endpoint was deemed not necessary by the Sponsor.

Conditions

Non-proliferative Diabetic Retinopathy

Interventions

DRUG: KSI-301
OTHER: Sham injection

Sponsor

Kodiak Sciences Inc